Dyslipidemia is highly prevalent and the primary direct driver of atherosclerotic CVD. In the more than 7 years since the last American Heart Association/American College of Cardiology/Multisociety Cholesterol guideline, there have been major advances in tests, tools and treatments to target dyslipidemia for improvement in CV health.
Column
Commentary
March 13, 2026
4 min read
Add topic to email alerts
Up to 21.5 million additional U.S. adults may be considered eligible for statin therapy based on newly updated dyslipidemia…
SCOTTSDALE, Ariz. — Criticism of the 2026 American Heart Association/American College of Cardiology/Multisociety Guideline on the…
PHILADELPHIA — With several lipoprotein(a) therapies nearing market availability, physicians at the Heart in Diabetes CME…
Studies assess population health impacts of the guideline on dyslipidemia
First Cholesterol Guidelines Update Since 2018: Check Earlier, Treat Sooner, and Aim Lower
SCOTTSDALE, Ariz. — Certain lipid parameters and biomarkers are better predictors of heart disease in women than LDL cholesterol…
